Table 1.

Associations with post-Covid PF. Abbreviations: L/O = length of, LOS = length of stay, f/u = follow-up, RR = respiratory rate, Sx = symptoms, CMs = comorbidities, pts = patients. * = compared to those with acute DAD, ** = compared to all other patterns of DAD. All associations are p < 0.05.

Study	N=	Criteria for Defining PF	Age	CMs	Medications	Ventilation	Labs
Yu, et al., 2020	32	Based on f/u CT; Pts put into 1 of 2 groups. Fibrosis group had evidence of fibrosis.	Older (Median 54 y.o, vs. 37)	HTN	Longer L/O steroid therapy, longer L/O antiviral therapy	–	Higher CRP, higher IL-6, lower lymphocytes
Hu, et al., 2020	76	Based on CT at discharge; Pts put into 1 of 2 groups. Fibrosis group showed presence of PF.	Older (Median 58 y.o, vs. 39)	HTN	–	–	Higher CRP, lower IFN-y, lower lymphocytes
Huang, et al., 2020	81	Based on f/u CT; Pts put into 1 of 2 groups: PF group showed fibrotic changes.	Older (Median 63 y.o, vs. 51)	HTN	More likely to have needed steroids	Higher rate of ventilation	Higher CRP, higher D-Dimer, lower lymphocytes
Li, Y. et al., 2020	30	Based on histopathology; Samples put into fibrosing DAD, acute, or organizing groups.	Younger * (Median 64 y.o, vs. 77)	–	–	Longer ventilation **	–